ADMA vs COLL
ADMA: ADMA manufactures and markets FDA-approved plasma-derived immune globulin products for immunodeficient and infectious disease patients, operating an integrated plasma collection and fractionation platform. COLL: A specialty pharma company building a diversified pain and ADHD portfolio through branded products and acquisitions, though facing material generic headwinds on its opioid franchise.
Side-by-side fundamentals
| Metric | ADMA | COLL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.38 | $34.72 | |
| Market cap as of 2026-07-23 | $2.0B | $1.1B | |
| P/E as of 2026-07-23 | 12.04 | 15.05 | ADMA lower |
| PEG as of 2026-07-23 | n/a | 13.08 | |
| Net margin as of 2026-07-23 | +32.4% | +9.4% | ADMA higher |
| Gross margin as of 2026-07-23 | +61.3% | +60.7% | ADMA higher |
| Operating margin as of 2026-07-23 | +41.5% | +21.7% | ADMA higher |
| ROE as of 2026-07-23 | +39.0% | +26.7% | ADMA higher |
| ROA as of 2026-07-23 | +27.4% | +4.6% | ADMA higher |
| Debt / equity as of 2026-07-23 | 0.50 | 2.57 | ADMA lower |
| Revenue growth (YoY) as of 2026-07-23 | +11.0% | +19.9% | COLL higher |
| Revenue CAGR (3y) SEC XBRL | +49.0% | +18.9% | ADMA higher |
| Beta as of 2026-07-23 | 0.79 | 0.77 | |
| 1-year return as of 2026-07-22 close | -49.9% | +16.0% | COLL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.